Flag of the European Union EU Clinical Trials Register Help

Clinical trials

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

  • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).


    The EU Clinical Trials Register currently displays   44335   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     

    < Back to search results

    Print Download

    Summary
    EudraCT Number:2021-003304-41
    Sponsor's Protocol Code Number:1397-0012
    National Competent Authority:France - ANSM
    Clinical Trial Type:EEA CTA
    Trial Status:Completed
    Date on which this record was first entered in the EudraCT database:2022-01-12
    Trial results
    Index
    A. PROTOCOL INFORMATION
    B. SPONSOR INFORMATION
    C. APPLICANT IDENTIFICATION
    D. IMP IDENTIFICATION
    D.8 INFORMATION ON PLACEBO
    E. GENERAL INFORMATION ON THE TRIAL
    F. POPULATION OF TRIAL SUBJECTS
    G. INVESTIGATOR NETWORKS TO BE INVOLVED IN THE TRIAL
    N. REVIEW BY THE COMPETENT AUTHORITY OR ETHICS COMMITTEE IN THE COUNTRY CONCERNED
    P. END OF TRIAL
    Expand All   Collapse All
    A. Protocol Information
    A.1Member State ConcernedFrance - ANSM
    A.2EudraCT number2021-003304-41
    A.3Full title of the trial
    A randomised, double-blind, placebo-controlled, parallel group, dose-finding study evaluating efficacy, safety and tolerability of BI 1291583 qd over at least 24 weeks in patients with bronchiectasis
    Etude randomisée, en double aveugle, contrôlée par placebo et en groupe
    parallèle, avec recherche de dose, évaluant l'efficacité, la sécurité et la
    tolérance d'une dose unique par jour du BI 1291583 sur au moins 24
    semaines chez des patients atteints de bronchectasie
    A.3.1Title of the trial for lay people, in easily understood, i.e. non-technical, language
    A study to test whether different doses of BI 1291583 help people with bronchiectasis
    Une étude visant à étudier si différentes doses du BI 1291583 peuvent
    aider les personnes atteintes de bronchectasie
    A.3.2Name or abbreviated title of the trial where available
    CatC inhibitor Phase II in bronchiectasis
    Etude phase II évaluant un inhibiteur de la CatC dans la bronchectasie
    A.4.1Sponsor's protocol code number1397-0012
    A.7Trial is part of a Paediatric Investigation Plan No
    A.8EMA Decision number of Paediatric Investigation Plan
    B. Sponsor Information
    B.Sponsor: 1
    B.1.1Name of SponsorBoehringer-Ingelheim France
    B.1.3.4CountryFrance
    B.3.1 and B.3.2Status of the sponsorCommercial
    B.4 Source(s) of Monetary or Material Support for the clinical trial:
    B.4.1Name of organisation providing supportBoehringer Ingelheim France
    B.4.2CountryFrance
    B.5 Contact point designated by the sponsor for further information on the trial
    B.5.1Name of organisationBoehringer Ingelheim Pharma GmbH & Co. KG
    B.5.2Functional name of contact pointCT Disclosure & Data Transparency
    B.5.3 Address:
    B.5.3.1Street AddressBinger Strasse 173
    B.5.3.2Town/ cityIngelheim am Rhein
    B.5.3.3Post code55216
    B.5.3.4CountryGermany
    B.5.4Telephone number+498002430127
    B.5.5Fax number+498008217119
    B.5.6E-mailclintriage.rdg@boehringer-ingelheim.com
    D. IMP Identification
    D.IMP: 1
    D.1.2 and D.1.3IMP RoleTest
    D.2 Status of the IMP to be used in the clinical trial
    D.2.1IMP to be used in the trial has a marketing authorisation No
    D.2.5The IMP has been designated in this indication as an orphan drug in the Community No
    D.2.5.1Orphan drug designation number
    D.3 Description of the IMP
    D.3.2Product code BI 1291583
    D.3.4Pharmaceutical form Tablet
    D.3.4.1Specific paediatric formulation No
    D.3.7Routes of administration for this IMPOral use
    D.3.8 to D.3.10 IMP Identification Details (Active Substances)
    D.3.8INN - Proposed INNNone yet
    D.3.9.1CAS number *MASKED*
    D.3.9.2Current sponsor codeBI 1291583
    D.3.9.3Other descriptive nameBI 1291583
    D.3.9.4EV Substance CodeSUB189070
    D.3.10 Strength
    D.3.10.1Concentration unit mg milligram(s)
    D.3.10.2Concentration typeequal
    D.3.10.3Concentration number1
    D.3.11 The IMP contains an:
    D.3.11.1Active substance of chemical origin Yes
    D.3.11.2Active substance of biological/ biotechnological origin (other than Advanced Therapy IMP (ATIMP) No
    The IMP is a:
    D.3.11.3Advanced Therapy IMP (ATIMP) No
    D.3.11.3.1Somatic cell therapy medicinal product No
    D.3.11.3.2Gene therapy medical product No
    D.3.11.3.3Tissue Engineered Product No
    D.3.11.3.4Combination ATIMP (i.e. one involving a medical device) No
    D.3.11.3.5Committee on Advanced therapies (CAT) has issued a classification for this product No
    D.3.11.4Combination product that includes a device, but does not involve an Advanced Therapy No
    D.3.11.5Radiopharmaceutical medicinal product No
    D.3.11.6Immunological medicinal product (such as vaccine, allergen, immune serum) No
    D.3.11.7Plasma derived medicinal product No
    D.3.11.8Extractive medicinal product No
    D.3.11.9Recombinant medicinal product No
    D.3.11.10Medicinal product containing genetically modified organisms No
    D.3.11.11Herbal medicinal product No
    D.3.11.12Homeopathic medicinal product No
    D.3.11.13Another type of medicinal product No
    D.IMP: 2
    D.1.2 and D.1.3IMP RoleTest
    D.2 Status of the IMP to be used in the clinical trial
    D.2.1IMP to be used in the trial has a marketing authorisation No
    D.2.5The IMP has been designated in this indication as an orphan drug in the Community No
    D.2.5.1Orphan drug designation number
    D.3 Description of the IMP
    D.3.2Product code BI 1291583
    D.3.4Pharmaceutical form Tablet
    D.3.4.1Specific paediatric formulation No
    D.3.7Routes of administration for this IMPOral use
    D.3.8 to D.3.10 IMP Identification Details (Active Substances)
    D.3.8INN - Proposed INNNone yet
    D.3.9.1CAS number *MASKED*
    D.3.9.2Current sponsor codeBI 1291583
    D.3.9.3Other descriptive nameBI 1291583
    D.3.9.4EV Substance CodeSUB189070
    D.3.10 Strength
    D.3.10.1Concentration unit mg milligram(s)
    D.3.10.2Concentration typeequal
    D.3.10.3Concentration number2.5
    D.3.11 The IMP contains an:
    D.3.11.1Active substance of chemical origin Yes
    D.3.11.2Active substance of biological/ biotechnological origin (other than Advanced Therapy IMP (ATIMP) No
    The IMP is a:
    D.3.11.3Advanced Therapy IMP (ATIMP) No
    D.3.11.3.1Somatic cell therapy medicinal product No
    D.3.11.3.2Gene therapy medical product No
    D.3.11.3.3Tissue Engineered Product No
    D.3.11.3.4Combination ATIMP (i.e. one involving a medical device) No
    D.3.11.3.5Committee on Advanced therapies (CAT) has issued a classification for this product No
    D.3.11.4Combination product that includes a device, but does not involve an Advanced Therapy No
    D.3.11.5Radiopharmaceutical medicinal product No
    D.3.11.6Immunological medicinal product (such as vaccine, allergen, immune serum) No
    D.3.11.7Plasma derived medicinal product No
    D.3.11.8Extractive medicinal product No
    D.3.11.9Recombinant medicinal product No
    D.3.11.10Medicinal product containing genetically modified organisms No
    D.3.11.11Herbal medicinal product No
    D.3.11.12Homeopathic medicinal product No
    D.3.11.13Another type of medicinal product No
    D.IMP: 3
    D.1.2 and D.1.3IMP RoleTest
    D.2 Status of the IMP to be used in the clinical trial
    D.2.1IMP to be used in the trial has a marketing authorisation No
    D.2.5The IMP has been designated in this indication as an orphan drug in the Community No
    D.2.5.1Orphan drug designation number
    D.3 Description of the IMP
    D.3.2Product code BI 1291583
    D.3.4Pharmaceutical form Tablet
    D.3.4.1Specific paediatric formulation No
    D.3.7Routes of administration for this IMPOral use
    D.3.8 to D.3.10 IMP Identification Details (Active Substances)
    D.3.8INN - Proposed INNNone yet
    D.3.9.1CAS number *MASKED*
    D.3.9.2Current sponsor codeBI 1291583
    D.3.9.3Other descriptive nameBI 1291583
    D.3.9.4EV Substance CodeSUB189070
    D.3.10 Strength
    D.3.10.1Concentration unit mg milligram(s)
    D.3.10.2Concentration typeequal
    D.3.10.3Concentration number5
    D.3.11 The IMP contains an:
    D.3.11.1Active substance of chemical origin Yes
    D.3.11.2Active substance of biological/ biotechnological origin (other than Advanced Therapy IMP (ATIMP) No
    The IMP is a:
    D.3.11.3Advanced Therapy IMP (ATIMP) No
    D.3.11.3.1Somatic cell therapy medicinal product No
    D.3.11.3.2Gene therapy medical product No
    D.3.11.3.3Tissue Engineered Product No
    D.3.11.3.4Combination ATIMP (i.e. one involving a medical device) No
    D.3.11.3.5Committee on Advanced therapies (CAT) has issued a classification for this product No
    D.3.11.4Combination product that includes a device, but does not involve an Advanced Therapy No
    D.3.11.5Radiopharmaceutical medicinal product No
    D.3.11.6Immunological medicinal product (such as vaccine, allergen, immune serum) No
    D.3.11.7Plasma derived medicinal product No
    D.3.11.8Extractive medicinal product No
    D.3.11.9Recombinant medicinal product No
    D.3.11.10Medicinal product containing genetically modified organisms No
    D.3.11.11Herbal medicinal product No
    D.3.11.12Homeopathic medicinal product No
    D.3.11.13Another type of medicinal product No
    D.8 Information on Placebo
    D.8 Placebo: 1
    D.8.1Is a Placebo used in this Trial?Yes
    D.8.3Pharmaceutical form of the placeboTablet
    D.8.4Route of administration of the placeboOral use
    D.8 Placebo: 2
    D.8.1Is a Placebo used in this Trial?Yes
    D.8.3Pharmaceutical form of the placeboTablet
    D.8.4Route of administration of the placeboOral use
    D.8 Placebo: 3
    D.8.1Is a Placebo used in this Trial?Yes
    D.8.3Pharmaceutical form of the placeboTablet
    D.8.4Route of administration of the placeboOral use
    E. General Information on the Trial
    E.1 Medical condition or disease under investigation
    E.1.1Medical condition(s) being investigated
    bronchiectasis
    Bronchectasie
    E.1.1.1Medical condition in easily understood language
    bronchiectasis
    Bronchectasie
    E.1.1.2Therapeutic area Diseases [C] - Respiratory Tract Diseases [C08]
    MedDRA Classification
    E.1.2 Medical condition or disease under investigation
    E.1.2Version 21.0
    E.1.2Level PT
    E.1.2Classification code 10006445
    E.1.2Term Bronchiectasis
    E.1.2System Organ Class 10038738 - Respiratory, thoracic and mediastinal disorders
    E.1.3Condition being studied is a rare disease No
    E.2 Objective of the trial
    E.2.1Main objective of the trial
    The primary objective of the trial is to assess a non-flat dose-response curve and to evaluate the dose-response relationship for 3 oral dose regimens of BI 1291583 versus placebo, on the primary endpoint, time to first pulmonary exacerbation up to 48 weeks.
    - Démontrer une courbe dose-réponse non plate,
    - Evaluer la relation dose-réponse pour 3 schémas posologiques oraux
    du BI 1291583 par rapport au placebo, sur le critère d'évaluation
    principal, le délai de survenue d'une première exacerbation pulmonaire
    jusqu'à 48 semaines
    E.2.2Secondary objectives of the trial
    The secondary objective is to assess superiority of BI 1291583 5 mg versus placebo on the primary endpoint, the time to first pulmonary exacerbation up to week 48, as well as on the secondary endpoint, the rate of pulmonary exacerbations up to week 48.
    Démontrer la supériorité du BI 1291583 5 mg par rapport au placebo
    - Sur le critère d'évaluation principal, le délai de survenue d'une
    première exacerbation pulmonaire jusqu'à la semaine 48, ainsi que
    - Sur le critère d'évaluation secondaire, le taux d'exacerbations
    pulmonaires jusqu'à la semaine 48.
    - Des comparaisons de traitement pour l'évaluation des objectifs
    primaires et secondaires seront effectuées sur tous les patients traités, y
    compris toutes les données jusqu'à la semaine 48
    E.2.3Trial contains a sub-study No
    E.3Principal inclusion criteria
    - Male or female (not of childbearing potential) patients
    - Age of patients when signing the informed consent ≥18 and ≤85 years.
    - Clinical history consistent with bronchiectasis (cough, chronic sputum production and/or recurrent respiratory infections) and investigator confirmed diagnosis of bronchiectasis by computed tomography (CT) scan.
    - History of pulmonary exacerbations requiring antibiotic treatment. In the 12 months before Visit 1, patients must have had either:
    -- at least 2 exacerbations, or
    -- at least 1 exacerbation and a SGRQ Symptoms score of >40 at screening visit 1.
    For patients on stable oral or inhaled antibiotics as chronic treatment for bronchiectasis, at least one exacerbation must have occurred since initiation of stable antibiotics.
    - Current sputum producers with a history of chronic expectoration
    1. Patients masculins ou féminins.
    Les femmes et les hommes en âge de procréer doivent s’abstenir des relations sexuelles et doivent utilisées des méthodes de contraception très efficaces selon l’ICH M3 (R2) utilisées de manière correcte tout au long de l’essai et pendant une période d’au moins 30 jours après la dernière prise de médicament à l’essai. Une liste des méthodes de contraception répondant à ces critères est fournie dans la rubrique 4.2.2.4 du protocole.
    2. Consentement éclairé daté et signé selon les bonnes pratiques cliniques (BPC) et la législation locale en vigueur avant l’entrée dans l’étude.
    3. Age des patients au moment de la signature du consentement éclairé ≥ 18 et ≤ 85 ans
    4. Antécédents cliniques compatibles avec la bronchectasie (toux, production chronique d’expectorations et/ou infections respiratoires récurrentes) et diagnostic de la bronchectasie confirmé par l’investigateur par tomodensitométrie (TMO). Les sujets dont les enregistrements radiographiques d’images thoraciques antérieures ne sont pas disponibles subiront une TMO à la visite de sélection. Les analyses antérieures ne doivent pas avoir plus de 5 ans
    5. Antécédents d’exacerbations pulmonaires nécessitant un traitement antibiotique. Au cours des 24 mois précédant la visite 1, les patients doivent avoir eu soit :
     au moins 2 exacerbations, ou
     au moins 1 exacerbation et un score de symptômes respiratoires SGRQ > 40 à visite 1.
    Pour les patients sous antibiotiques oraux ou inhalés stables comme traitement chronique de la bronchectasie, au moins une exacerbation doit s’être produite depuis l’initiation des doses stables d’antibiotiques (voir rubrique 4.2.2.1: 1 du protocole).
    6. Patients produisant actuellement des expectorations et ayant des antécédents d’expectoration chronique qui sont en mesure de fournir un échantillon d’expectoration spontané (non induit) à la visite 1.
    E.4Principal exclusion criteria
    - AST and / or ALT >3.0 x ULN at Visit 1
    - Estimated glomerular filtration rate (eGFR) according to CKD-EPI formula < 30 mL/min at Visit 1.
    - An absolute blood neutrophil count <1,000/mm3 at Visit 1.
    - Any clinically relevant finding in the medical examination (including BP, PR, or ECG) and/or laboratory value assessed by the Investigator at Screening Visit 1 or during screening period.
    - Positive serological tests for hepatitis B, hepatitis C, or human immunodeficiency virus (HIV) infection, or known infection status.
    - A current diagnosis of
    -- Cystic Fibrosis
    -- Hypogammaglobulinemia
    -- Common variable immunodeficiency
    -- α1-antitrypsin deficiency
    -- Allergic bronchopulmonary aspergillosis requiring treatment
    -- Tuberculosis or non tuberculous mycobacterial infection being treated or requiring treatment according to local guidelines
    -- Palmoplantar keratosis; or keratoderma climactericum
    -- Hypothyroidism, myxedema, chronic lymphedema with associated hyperkeratosis of the skin, acrocyanosis. If a subject has hypothyroidism but is treated and compensated, the subject is allowed into the trial
    -- Psoriasis affecting palms and soles; or body surface area for psoriasis ≥ 10%
    -- Reactive arthritis (Reiter’s syndrome); keratoderma blennorrhagicum
    -- Pityriasis rubra pilaris
    -- Atopic dermatitis affecting palms and soles; or body surface area for atopic dermatitis ≥ 10%.
    -- Active extensive verruca vulgaris, as per investigator’s discretion
    -- Active fungal infection of hand and/or feet not adequately treated and responsive to antifungal therapy, as per investigator’s discretion
    - Any acute infections (including respiratory infections) defined as infections requiring systemic or inhaled antibiotic therapy within 4 weeks prior Visit 1 and throughout screening.
    - Any evidence of a concomitant disease, such as Papillon-Lefevre Syndrome, relevant pulmonary, gastrointestinal, hepatic, renal, cardiovascular, metabolic, immunological, or hormonal disorders.
    - Received any live attenuated vaccine within 4 weeks prior to Visit 2.
    - Medical conditions associated with periodontal disease (to be evaluated by a periodontist or dentist).
    - Patients who must or wish to continue the intake of restricted medications or any drug considered likely to interfere with the safe conduct of the trial.

    Further criteria apply.
    1. AST et / ou ALT > 3.0 x ULN à la visite 1.
    2. Débit de filtration glomérulaire estimé (DFGe) selon la formule CKD-EPI < 30 mL/min à la visite 1.
    3. Nombre absolu de neutrophiles sanguins <1 000/mm3 à la visite 1.
    4. Toute observation cliniquement pertinente lors de l’examen médical (y compris la PA (pression artérielle), le pouls ou l’ECG) et/ou la valeur de laboratoire évaluée par l’investigateur lors de la visite 1 ou la période de sélection.
    [Les paramètres de laboratoire à la visite 1 doivent correspondre aux valeurs seuils de laboratoire indiquées ci-dessus. Les résultats du laboratoire de la visite 2 ne seront disponibles qu’après randomisation. Dans le cas où, lors de la visite 2, les résultats ne répondent plus aux critères d’éligibilité, l’investigateur doit décider s’il est justifié de garder le patient dans l’essai. La justification de la décision doit être documentée.].
    5. Tests sérologiques positifs pour l’hépatite B, l’hépatite C ou infection connue pour le virus de l’immunodéficience humaine (VIH) ou statut d’infection connu.
    Diagnostic et traitement concomitants
    6. Un diagnostic actuel de :
    a. Mucoviscidose (CF).
    b. Hypogammaglobulinémie.
    c. Déficit Immunitaire commun variable (DICV).
    d. Déficit en α1-antitrypsine.
    e. Aspergillose bronchopulmonaire allergique nécessitant un traitement.
    f. Tuberculose ou infection à mycobactéries non tuberculeuse traitée ou nécessitant un traitement selon les directives locales.
    g. Infection aiguë par le SRAS-CoV-2.
    h. Kératose palmoplantaire ; ou kératodermie climactérique.
    i. Hypothyroïdie, myxœdème, lymphœdème chronique avec hyperkératose associée de la peau, acrocyanose. Si un sujet a une hypothyroïdie mais est traité et indemnisé, le sujet est autorisé à entrer dans l’essai.
    j. Psoriasis affectant les paumes et la plante des patients ; ou la surface corporelle atteinte par le psoriasis ≥ 10%.
    k. Arthrite réactionnel (syndrome de Reiter), kératodermie blennorragique.
    l. Ptyriasis rosé de Gilbert.
    m. Dermatite atopique affectant les paumes et la plante des pieds des patients ; ou la surface corporelle de la dermatite atopique ≥ 10%.
    n. Verrue vulgaire étendue et active, selon l’avis de l’investigateur.
    o. Infection fongique active de la main et/ou des pieds non traitée adéquatement et ne répondant pas au traitement antifongique, selon l’avis de l’investigateur.
    7. Toute infection aiguë (y compris les infections respiratoires) définie comme des infections nécessitant une antibiothérapie systémique ou inhalée dans les 4 semaines précédant la visite 1 et tout au long de la période de sélection.
    8. Toute preuve d’une maladie concomitante, telle que le syndrome de Papillon-Lefevre, des troubles pulmonaires, gastro-intestinaux, hépatiques, rénaux, cardiovasculaires, métaboliques, immunologiques ou hormonaux pertinents, qui, de l’avis de l’investigateur, peut mettre le patient en danger en participant à l’étude.
    9. Patient ayant reçu un vaccin vivant atténué dans les 4 semaines précédant la visite 2.
    10. Conditions médicales associées à la maladie parodontale (à évaluer par un parodontiste ou un dentiste) a) Toute dent qui peut potentiellement être douloureuse ou infectée lors de l’examen buccal sauf si elle est soignée avant la participation à l’essai (p. ex. nécrose de la pulpe).
    b) Maladie parodontale sévère avec une profondeur de poche mesurée ≥ 6 mm sur 2 dents ou plus.
    c) Furcation d’une dent de classe 3 (correspond à des lésions transfixiantes à l’endroit où les racines commencent à diverger dans l’alvéole osseuse) ou participation à la furcation d’une dent de classe 3.
    d) Extraction dentaire programmée pendant la période de l’essai.
    11. Patients qui doivent ou souhaitent continuer à prendre des médicaments interdits (voir rubrique 4.2.2.1 du protocole) ou tout traitement considéré comme susceptible d’interférer avec le bon déroulement de l’essai.

    autres critères s'appliquent
    E.5 End points
    E.5.1Primary end point(s)
    1) Time to first pulmonary exacerbation up to 48 weeks after first drug adminstration
    Délai de survenue de première exacerbation pulmonaire jusqu'à 48 semaines après la première administration du traitement à l'étude
    E.5.1.1Timepoint(s) of evaluation of this end point
    1) week 48
    1) 48 semaines
    E.5.2Secondary end point(s)
    1) Relative change from baseline in neutrophil elastase (NE) activity in sputum at week 12 after first drug administration
    2) Rate of pulmonary exacerbations (number of events per person-time) up to week 48 after first drug administration
    3) Absolute change from baseline in St. George’s Respiratory Questionnaire (SGRQ) Symptoms score at week 24 after first drug administration
    4) Absolute change from baseline in percent predicted post-bronchodilator forced expiratory volume in one second (FEV1%pred) at week 24 after first drug administration
    5) Occurrence of an exacerbation by week 24 after first drug administration
     Changement relatif de l’activité de l’élastase neutrophile (EN) dans les expectorations par rapport à la valeur initiale (baseline) à la semaine 12 après la première administration du traitement à l’étude.
     Taux d’exacerbations pulmonaires (nombre d’événements par patient-temps) jusqu’à la semaine 48 après la première administration du traitement à l’étude.
     Changement absolu du score du questionnaire de saint Georges sur les problèmes respiratoires (SGRQ) par rapport à la baseline à la semaine 24 après la première administration du traitement à l’étude.
     Variation absolue par rapport à baseline en pourcentage du volume expiratoire forcé post-bronchodilatateur prédit en une seconde (VEMS1 en pourcentage de la valeur prédite) à la semaine 24.
     Apparition d’une exacerbation à la semaine 24 après la première administration du traitement à l’étude.
    E.5.2.1Timepoint(s) of evaluation of this end point
    1) week 12
    2) up to week 48
    3) week 24
    4) week 24
    5) week 24
    1) 12 semaines
    2) jusqu'à 48 semaines
    3) 24 semaines
    24 semaines
    5) 24 semaines
    E.6 and E.7 Scope of the trial
    E.6Scope of the trial
    E.6.1Diagnosis No
    E.6.2Prophylaxis No
    E.6.3Therapy Yes
    E.6.4Safety Yes
    E.6.5Efficacy Yes
    E.6.6Pharmacokinetic Yes
    E.6.7Pharmacodynamic Yes
    E.6.8Bioequivalence No
    E.6.9Dose response Yes
    E.6.10Pharmacogenetic No
    E.6.11Pharmacogenomic No
    E.6.12Pharmacoeconomic No
    E.6.13Others No
    E.7Trial type and phase
    E.7.1Human pharmacology (Phase I) No
    E.7.1.1First administration to humans No
    E.7.1.2Bioequivalence study No
    E.7.1.3Other No
    E.7.1.3.1Other trial type description
    E.7.2Therapeutic exploratory (Phase II) Yes
    E.7.3Therapeutic confirmatory (Phase III) No
    E.7.4Therapeutic use (Phase IV) No
    E.8 Design of the trial
    E.8.1Controlled Yes
    E.8.1.1Randomised Yes
    E.8.1.2Open No
    E.8.1.3Single blind No
    E.8.1.4Double blind Yes
    E.8.1.5Parallel group Yes
    E.8.1.6Cross over No
    E.8.1.7Other No
    E.8.2 Comparator of controlled trial
    E.8.2.1Other medicinal product(s) No
    E.8.2.2Placebo Yes
    E.8.2.3Other No
    E.8.2.4Number of treatment arms in the trial4
    E.8.3 The trial involves single site in the Member State concerned No
    E.8.4 The trial involves multiple sites in the Member State concerned No
    E.8.5The trial involves multiple Member States Yes
    E.8.5.1Number of sites anticipated in the EEA65
    E.8.6 Trial involving sites outside the EEA
    E.8.6.1Trial being conducted both within and outside the EEA Yes
    E.8.6.2Trial being conducted completely outside of the EEA No
    E.8.6.3If E.8.6.1 or E.8.6.2 are Yes, specify the regions in which trial sites are planned
    Belgium
    Bulgaria
    Canada
    Czechia
    Denmark
    France
    Germany
    Greece
    Hungary
    Ireland
    Israel
    Italy
    Japan
    Korea, Republic of
    Latvia
    Mexico
    Netherlands
    New Zealand
    Poland
    Portugal
    Russian Federation
    Spain
    Turkey
    Ukraine
    United Kingdom
    United States
    E.8.7Trial has a data monitoring committee Yes
    E.8.8 Definition of the end of the trial and justification where it is not the last visit of the last subject undergoing the trial
    LVLS
    dernier patient sortie d'étude
    E.8.9 Initial estimate of the duration of the trial
    E.8.9.1In the Member State concerned years1
    E.8.9.1In the Member State concerned months11
    E.8.9.1In the Member State concerned days
    E.8.9.2In all countries concerned by the trial years1
    E.8.9.2In all countries concerned by the trial months11
    F. Population of Trial Subjects
    F.1 Age Range
    F.1.1Trial has subjects under 18 No
    F.1.1.1In Utero No
    F.1.1.2Preterm newborn infants (up to gestational age < 37 weeks) No
    F.1.1.3Newborns (0-27 days) No
    F.1.1.4Infants and toddlers (28 days-23 months) No
    F.1.1.5Children (2-11years) No
    F.1.1.6Adolescents (12-17 years) No
    F.1.2Adults (18-64 years) Yes
    F.1.2.1Number of subjects for this age range: 100
    F.1.3Elderly (>=65 years) Yes
    F.1.3.1Number of subjects for this age range: 140
    F.2 Gender
    F.2.1Female Yes
    F.2.2Male Yes
    F.3 Group of trial subjects
    F.3.1Healthy volunteers No
    F.3.2Patients Yes
    F.3.3Specific vulnerable populations No
    F.3.3.1Women of childbearing potential not using contraception No
    F.3.3.2Women of child-bearing potential using contraception No
    F.3.3.3Pregnant women No
    F.3.3.4Nursing women No
    F.3.3.5Emergency situation No
    F.3.3.6Subjects incapable of giving consent personally No
    F.3.3.7Others No
    F.4 Planned number of subjects to be included
    F.4.1In the member state10
    F.4.2 For a multinational trial
    F.4.2.1In the EEA 131
    F.4.2.2In the whole clinical trial 240
    F.5 Plans for treatment or care after the subject has ended the participation in the trial (if it is different from the expected normal treatment of that condition)
    None
    aucun
    G. Investigator Networks to be involved in the Trial
    N. Review by the Competent Authority or Ethics Committee in the country concerned
    N.Competent Authority Decision Authorised
    N.Date of Competent Authority Decision2022-03-10
    N.Ethics Committee Opinion of the trial applicationFavourable
    N.Ethics Committee Opinion: Reason(s) for unfavourable opinion
    N.Date of Ethics Committee Opinion2022-03-09
    P. End of Trial
    P.End of Trial StatusCompleted
    P.Date of the global end of the trial2024-05-30
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Fri May 09 14:54:02 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA